Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Krenn, M; Sener, M; Rath, J; Zulehner, G; Keritam, O; Wagner, M; Laccone, F; Iglseder, S; Marte, S; Baumgartner, M; Eisenkölbl, A; Liechtenstein, C; Rudnik, S; Quasthoff, S; Grinzinger, S; Spenger, J; Wortmann, SB; Löscher, WN; Zimprich, F; Kellersmann, A; Rappold, M; Bernert, G; Freilinger, M; Cetin, H.
The clinical and molecular landscape of congenital myasthenic syndromes in Austria: a nationwide study.
J NEUROL. 2022; Doi: 10.1007/s00415-022-11440-0
Web of Science PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Quasthoff Stefan

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

BACKGROUND: Congenital myasthenic syndromes (CMS) are a heterogeneous group of disorders caused by genetic defects resulting in impaired neuromuscular transmission. Although effective treatments are available, CMS is probably underdiagnosed, and systematic clinico-genetic investigations are warranted. METHODS: We used a nationwide approach to collect Austrian patients with genetically confirmed CMS. We provide a clinical and molecular characterization of this cohort and aimed to ascertain the current frequency of CMS in Austria. RESULTS: Twenty-eight cases with genetically confirmed CMS were identified, corresponding to an overall prevalence of 3.1 per million (95% CI 2.0-4.3) in Austria. The most frequent genetic etiology was CHRNE (n = 13), accounting for 46.4% of the cohort. Within this subgroup, the variant c.1327del, p.(Glu443Lysfs*64) was detected in nine individuals. Moreover, causative variants were found in DOK7 (n = 4), RAPSN (n = 3), COLQ (n = 2), GMPPB (n = 2), CHAT (n = 1), COL13A1 (n = 1), MUSK (n = 1) and AGRN (n = 1). Clinical onset within the first year of life was reported in one half of the patients. Across all subtypes, the most common symptoms were ptosis (85.7%), lower limb (67.9%), upper limb (60.7%) and facial weakness (60.7%). The majority of patients (96.4%) received specific treatment, including acetylcholinesterase inhibitors in 20, adrenergic agonists in 11 and 3,4-diaminopyridine in nine patients. CONCLUSIONS: Our study presents the first systematic characterization of individuals with CMS in Austria, providing prevalence estimates and genotype-phenotype correlations that may help to improve the diagnostic approach and patient management.

Find related publications in this database (Keywords)
Congenital myasthenic syndrome
© Med Uni Graz Impressum